SCHEMBL511713

SCHEMBL511713

Clc1ccc(Cl)c2o[c]nc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10832767 0.70 CYP3A4 (0.33)
SCHEMBL940307 0.70 PSMB8 (0.41)
SCHEMBL11205296 0.67 DPP4 (0.31)
SCHEMBL11498155 0.55 TDP1 (0.43)
SCHEMBL198192 0.55 KDM4E (0.43)
SCHEMBL11231499 0.53
SCHEMBL196536 0.51 KDM4E (0.70)
SCHEMBL10305605 0.51 MAPT (0.36)
SCHEMBL2580203 0.50
SCHEMBL18938657 0.50

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1121129-B1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS BRISTOL MYERS SQUIBB CO (US) 2008-09-03 EP claimed
US-20040229807-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2004-11-18 US claimed
EP-1449835-A2 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds PHARMACIA &amp; UPJOHN COMPANY (US) 2004-08-25 EP claimed
EP-1121129-A4 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL MYERS SQUIBB CO (US) 2002-10-16 EP claimed
EP-1247804-A1 Pyrimidine-thioalkyl and alkylether compounds PHARMACIA &amp; UPJOHN COMPANY (US) 2002-10-09 EP claimed
EP-1113801-A4 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL MYERS SQUIBB CO (US) 2002-10-02 EP claimed
JP-2002524517-A 2002-08-06 JP claimed
JP-2002524518-A 2002-08-06 JP claimed
US-20020035064-A1 Method for treating atherosclerosis employing an aP2 inhibitor and combination BRISTOL-MYERS SQUIBB COMPANY 2002-03-21 US claimed
EP-1121129-A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-08 EP claimed
WO-1999019304-A9 ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS UPJOHN CO (US) 1999-07-08 WO claimed
WO-1999019304-A2 ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 1999-04-22 WO claimed
EP-0824524-A1 ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE PHARMACIA &amp; UPJOHN COMPANY (US) 1998-02-25 EP claimed
WO-1996035678-A1 ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE PHARMACIA & UPJOHN COMPANY (US) 1996-11-14 WO claimed
EP-0728130-A1 PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS PHARMACIA &amp; UPJOHN COMPANY (US) 1996-08-28 EP claimed
WO-1995013267-A1 PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS THE UPJOHN COMPANY (US) 1995-05-18 WO claimed
US-5308854-A 2-benzoxazolylalkyl substituted pyridin-2(1H)(thi)ones; AIDS MERCK & CO., INC. (US) 1994-05-03 US claimed
EP-0507488-A1 Inhibitors of HIV-1 reverse transcriptase MERCK & CO. INC. (US) 1992-10-07 EP claimed
EP-0481802-A1 Hydroxylated inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1992-04-22 EP claimed
EP-0462800-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP claimed